<DOC>
	<DOCNO>NCT01930474</DOCNO>
	<brief_summary>The presence genetic alteration tyrosine kinase domain oncogene ( eg . EGFR ALK ) associate clinical response tyrosine kinase inhibitor ( TKIs ) patient non-small cell lung cancer . Therefore , detection alter genetic alteration useful predict treatment response TKIs non-small cell lung cancer patient . However , good quality tumor tissue available &lt; 50 % patient inoperable lung cancer mutation analysis . In study , investigator detect quantify genetic alteration plasma . investigator investigate serial measurement cancer-derived genetic alteration plasma provide mean monitoring disease progression , well treatment response . In addition investigator analysis resistant mechanism TKIs chemotherapy plasma tumor DNA .</brief_summary>
	<brief_title>Analysis Plasma Tumor DNA Lung Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Have histologically cytologically confirm diagnosis nonsmall cell lung cancer Have molecular evidence genetic alteration tumor sample ( eg . EGFR mutation , ALK fusion ) Patients must give write informed consent Patients refuse blood sampling</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>lung cancer , plasma DNA , free DNA , EGFR , ALK</keyword>
</DOC>